To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.
DRAVP ID DRAVPa1867
Peptide Name Sequence 66 from Patent US20240309059 A1
Sequence WEEWDKKIEEYTKKIEELIKKSONOOIDL
Sequence Length 29
Source Synthetic construct
Target Organism HIV
Patent Type Patent Application
Publication Date 2017-03-29
Patent No CN106543273 A
Patent Title Polypeptide for inhibiting HIV infection and medicinal application thereof
Comment
Abstract The invention belongs to the field of biological medicine and relates to an anti-HIV infection peptide, in particular to a polypeptide shown by a formula 1 CP_I(L)_D_I (L), its derivatives, its stereoisomers, or its salts free of physiological toxicity. CP in the formula represents a C-terminal polypeptide derived from HIV-1 gp41 and having HIV-1 inhibiting activity, L represents leucine, I represents isoleucine, and D represents aspartic acid. Variable amino acid is added to the carbon terminal of the C-terminal polypeptide having the HIV-1 inhibiting activity to obtain a longer polypeptide, so that the polypeptide has remarkable strengthened antiviral activity. The invention further relates to a drug composition containing the polypeptide shown by the formula 1, its derivatives, its stereoisomers or its salts free of physiological toxicity and application in preparation of drugs for treating or preventing related diseases caused by HIV infection, especially acquired immune deficiency syndrome.
To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.